ライフサイエンスコーパス: protein synthesis inhibitor

1 osynthesis inhibitor) and chloramphenicol (a protein synthesis inhibitor).

2 protein kinase II (CaMKII) inhibitors and a protein synthesis inhibitor.

3 triggers p100 processing in the presence of protein synthesis inhibitor.

4 is blocked by the presence of anisomycin, a protein synthesis inhibitor.

5 N varicosities were blocked by anisomycin, a protein synthesis inhibitor.

6 rin gene expression, even in the presence of protein synthesis inhibitor.

7 by measuring the coentry of alpha-sarcin, a protein synthesis inhibitor.

8 nfections are performed in the presence of a protein synthesis inhibitor.

9 Here, we demonstrate that mefloquine is a protein synthesis inhibitor.

10 erm treatment with lincomycin, a chloroplast protein synthesis inhibitor.

11 h, which was unaffected by pretreatment with protein synthesis inhibitor.

12 s venezuelae, represent minimalist macrolide protein synthesis inhibitors.

13 ith cell wall active antibiotics rather than protein synthesis inhibitors.

14 we explored the effect of several eukaryotic protein synthesis inhibitors.

15 polymerization were completely suppressed by protein synthesis inhibitors.

16 epatocytes within 24 hours in the absence of protein synthesis inhibitors.

17 ive-strand RNAs in the presence of different protein synthesis inhibitors.

18 sensitive than wild-type strains to certain protein synthesis inhibitors.

19 LTD has a late phase that may be blocked by protein synthesis inhibitors.

20 antly affect ongoing P-LTF in the absence of protein synthesis inhibitors.

21 EC) produces Shiga-like toxins (SLT), potent protein synthesis inhibitors.

22 nocodazole-treated cells in the presence of protein synthesis inhibitors.

23 comprise an important class of antibacterial protein synthesis inhibitors.

24 rowth factor pathway by its insensitivity to protein synthesis inhibitors.

25 pressing P-LTF in the absence or presence of protein synthesis inhibitors.

26 mpounds, including 5a and 5k, seem to act as protein synthesis inhibitors.

27 s can be directly modulated by commonly used protein synthesis inhibitors.

28 me serotypes of Escherichia coli, are potent protein synthesis inhibitors.

29 d when hippocampal neurons were treated with protein synthesis inhibitors.

30 glucocorticoids, microtubule inhibitors, and protein synthesis inhibitors.

31 esia vary substantially after treatment with protein synthesis inhibitors.

32 xamined this hypothesis by local infusion of protein-synthesis inhibitor after devaluation of a food

33 Genomic modulators including a protein synthesis inhibitor, an RNA synthesis inhibitor,

34 This effect occurred in the presence of a protein synthesis inhibitor and also in the absence of m

35 ein kinase inhibitor staurosporine, with the protein synthesis inhibitor and protein kinase activator

36 Stxs are potent protein synthesis inhibitors and are the primary virulen

37 AR1 or LTV1 are hypersensitive to particular protein synthesis inhibitors and exhibit aberrant polyso

38 hepatocyte cultures using a broader array of protein synthesis inhibitors and experimental end points

39 g sensitivities to low temperatures, certain protein synthesis inhibitors and high osmolarity.

40 transcription factors, apoptosis regulators, protein synthesis inhibitors and protein degradation fac

41 of transcription, homoharringtonine (HHT), a protein synthesis inhibitor, and imatinib were used sing

42 We found that both cycloheximide, a general protein synthesis inhibitor, and rapamycin, a selective

43 nd GABAB receptors, occur in the presence of protein synthesis inhibitors, and are not influenced by

44 stimuli such as heat shock, UV irradiation, protein synthesis inhibitors, and conditions that elevat

45 his factor, that persists in the presence of protein synthesis inhibitors, and that is therefore medi

46 h a specific context, and the ability of the protein synthesis inhibitor anisomycin administered foll

47 Biedenkapp and J. W. Rudy reported that the protein synthesis inhibitor anisomycin administered into

48 c or intra-hippocampal administration of the protein synthesis inhibitor anisomycin generally leads t

49 at the impairments in behavior caused by the protein synthesis inhibitor anisomycin given after retri

50 The presence of the protein synthesis inhibitor anisomycin had no effect on

51 mpus 48 h after contextual training with the protein synthesis inhibitor anisomycin impaired memory p

52 Infusion of the protein synthesis inhibitor anisomycin into the LBA shor

53 The protein synthesis inhibitor anisomycin was administered

54 ependent LTD in AS mice was sensitive to the protein synthesis inhibitor anisomycin, and relied on th

55 ion training, followed by treatment with the protein synthesis inhibitor anisomycin, LTS was disrupte

56 ppocampal infusions of vehicle (VEH), of the protein synthesis inhibitor anisomycin, of the D1/D5 dop

57 Both responses were blocked by the protein synthesis inhibitor anisomycin.

58 nosylbenzimidazole (DRB), or infusion of the protein synthesis inhibitor anisomycin.

59 of rapamycin inhibitor temsirolimus and the protein synthesis inhibitor anisomycin.

60 gen peroxide, menadione, heat shock, and the protein synthesis inhibitor anisomycin.

61 e inhibited period was also inhibited by the protein synthesis inhibitor anisomycin.

62 In contrast, the protein synthesis inhibitors anisomycin and puromycin di

63 s effect is antagonized by administration of protein synthesis inhibitors anisomycin and rapamycin in

64 h were prevented by local application of the protein synthesis inhibitors anisomycin or rapamycin.

65 + MPEP) and their induction was prevented by protein synthesis inhibitor (anisomycin).

66 a transcription inhibitor (actinomycin D) or protein synthesis inhibitors (anisomycin or cycloheximid

67 Animals treated with the protein synthesis inhibitor, anisomycin, into either the

68 Infusions of the protein synthesis inhibitor, anisomycin, prior to defeat

69 eam cellular activation was prevented when a protein synthesis inhibitor, anisomycin, was administere

70 ion, which was inhibited by intrahippocampal protein synthesis inhibitor anisomysin, D1/D5 dopaminerd

71 Protein synthesis inhibitor antibiotics are widely used

72 lts suggest that (1) the amnestic effects of protein synthesis inhibitors are confounded by neural si

73 signaling is delayed and can be inhibited by protein synthesis inhibitor as well as why most classica

74 the data identify microtubule inhibitors and protein synthesis inhibitors as modulators of PGC-1alpha

75 actinomycin D (Act D, 20 micromol/L; n=6), a protein synthesis inhibitor at the transcriptional level

76 d with cycloheximide (CHx, 10 micromol/L), a protein synthesis inhibitor at the translational level,

77 Protein synthesis inhibitors block mossy fiber(MF) LTP m

78 Protein synthesis inhibitors block the maintenance of NM

79 RNA synthesis inhibitor) or cycloheximide (a protein synthesis inhibitor) blocked ganglionic movement

80 Bath application of emetine, a protein synthesis inhibitor, blocked eCB-LTD after affer

81 hrine-deprived conditions in the presence of protein synthesis inhibitor, both the IP3 response and t

82 not only be a function of hygromycin B as a protein synthesis inhibitor but also possibly related to

83 Restoration occurred in the presence of a protein synthesis inhibitor but not after a transcriptio

84 lic inhibitors revealed that cycloheximide a protein synthesis inhibitor, but not phosphonoacetic aci

85 mulation was insensitive to cycloheximide, a protein synthesis inhibitor, but was completely inhibite

86 lease was not diminished by transcription or protein synthesis inhibitors, but was suppressed by bref

87 A brief treatment of the cells with a protein synthesis inhibitor can abolish okadaic acid-ind

88 owever, old memories that are insensitive to protein synthesis inhibitors can become vulnerable if th

89 d by the production of new proteins, because protein synthesis inhibitors can block retrieval of rece

90 e resulting compendium revealed, first, that protein synthesis inhibitors can decouple coordination o

91 nse was cycloheximide-sensitive, because the protein synthesis inhibitor caused a GC-dependent superi

92 lls expressing the transfected TRH receptor, protein synthesis inhibitors caused translocation of int

93 Treatment of E. coli cells with the protein synthesis inhibitor chloramphenicol abolished re

94 The protein synthesis inhibitor chloramphenicol prevents the

95 ell-wall-active antibiotic ampicillin or the protein synthesis inhibitor clindamycin or azithromycin.

96 We found that addition of the protein synthesis inhibitor clindamycin to S. aureus LAC

97 occurs in cells that have been treated with protein synthesis inhibitors, consistent with a displace

98 Here, we report that specific protein synthesis inhibitors could either significantly

99 anscription inhibitor actinomycin D, and the protein synthesis inhibitor cyclohexamide suggest that M

100 The eukaryotic protein synthesis inhibitor cycloheximid has been used b

101 bitor actinomycin-D (0.5 microg ml(-1)), the protein synthesis inhibitor cycloheximide (1 microg ml(-

102 e GR antagonist RU-486 (1-10 microM), or the protein synthesis inhibitor cycloheximide (1 microM) fai

103 ect, HCjE cells were treated with RA and the protein synthesis inhibitor cycloheximide (1.0 microg/mL

104 llowing harmful ischemia were blocked by the protein synthesis inhibitor cycloheximide (1.0 muM), a k

105 he generation of IL-8 during chemotaxis, the protein synthesis inhibitor cycloheximide (10 microg/ml)

106 The protein synthesis inhibitor cycloheximide (10 microg/ml)

107 ycin was verified using a single dose of the protein synthesis inhibitor cycloheximide (40 nmol).

108 nt cells and sensitivity was restored by the protein synthesis inhibitor cycloheximide (CHX) and the

109 ment of exponentially growing cells with the protein synthesis inhibitor cycloheximide (CHX) confirms

110 The ability of the protein synthesis inhibitor cycloheximide (CHX) to preve

111 fects of PAF antagonist BN50730 (10 microM), protein synthesis inhibitor cycloheximide (CHX; 30 micro

112 thesis, the authors gave spinalized rats the protein synthesis inhibitor Cycloheximide (CXM) or salin

113 Treatment of TM cells with the protein synthesis inhibitor cycloheximide abolished the

114 Administration of the protein synthesis inhibitor cycloheximide after training

115 The protein synthesis inhibitor cycloheximide also has a cyt

116 is protective effect could be blocked by the protein synthesis inhibitor cycloheximide and by a varie

117 Both the protein synthesis inhibitor cycloheximide and cyclin E a

118 The protein synthesis inhibitor cycloheximide and the protea

119 y ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appea

120 f HMGI-C mRNA level is sensitive to both the protein synthesis inhibitor cycloheximide and transcript

121 induced by 1S,3R-ACPD was attenuated by the protein synthesis inhibitor cycloheximide as well as by

122 te early gene, pretreatment of mice with the protein synthesis inhibitor cycloheximide before either

123 NA synthesis inhibitor actinomycin D and the protein synthesis inhibitor cycloheximide both completel

124 thesis of this transcript was blocked by the protein synthesis inhibitor cycloheximide but not by the

125 stigated whether induction of c-Myc by OA or protein synthesis inhibitor cycloheximide contributed to

126 The protein synthesis inhibitor cycloheximide decreased GnRH

127 The eukaryotic protein synthesis inhibitor cycloheximide did not block

128 Whereas the protein synthesis inhibitor cycloheximide did not block

129 The protein synthesis inhibitor cycloheximide did not block

130 Because the protein synthesis inhibitor cycloheximide did not preven

131 n of STAT6, and is blocked by the reversible protein synthesis inhibitor cycloheximide during the IL-

132 onfluent OCCM cells were pretreated with the protein synthesis inhibitor cycloheximide followed by fl

133 must be maintained by recycling, because the protein synthesis inhibitor cycloheximide has no effect

134 Slowing the translation rate with the protein synthesis inhibitor cycloheximide increased the

135 bitors SB202190 and SB203580 and the general protein synthesis inhibitor cycloheximide inhibited both

136 ylation and that treatment of cells with the protein synthesis inhibitor cycloheximide led to an almo

137 The protein synthesis inhibitor cycloheximide markedly (P<.0

138 increase in CCL20 levels was not affected by protein synthesis inhibitor cycloheximide nor protein tr

139 r in vivo intravitreal administration of the protein synthesis inhibitor cycloheximide or lactacystin

140 Treatment with the protein synthesis inhibitor cycloheximide or RNA interfe

141 is increased by co-treatment with either the protein synthesis inhibitor cycloheximide or the phospha

142 The protein synthesis inhibitor cycloheximide potentiated EM

143 Pretreating the animals with protein synthesis inhibitor cycloheximide prevented I/R-

144 in thyroid cells, whereas treatment with the protein synthesis inhibitor cycloheximide prior to Fas a

145 Experiments performed with the protein synthesis inhibitor cycloheximide provided evide

146 Kinetic studies using the protein synthesis inhibitor cycloheximide showed that TR

147 The protein synthesis inhibitor cycloheximide significantly

148 ections of mGluR1 antagonist JNJ16259685 and protein synthesis inhibitor cycloheximide significantly

149 eins after UV exposure or treatment with the protein synthesis inhibitor cycloheximide were similar.

150 cular and intrahippocampal injections of the protein synthesis inhibitor cycloheximide, administered

151 e cultured in the presence or absence of the protein synthesis inhibitor cycloheximide, and prorenin

152 cluding the immunosuppressant rapamycin, the protein synthesis inhibitor cycloheximide, and several p

153 SA was potent, rapid, and insensitive to the protein synthesis inhibitor cycloheximide, and we conclu

154 ightfold within 6 h after treatment with the protein synthesis inhibitor cycloheximide, but simultane

155 is when administered in combination with the protein synthesis inhibitor cycloheximide, but the apopt

156 atory O2 uptake by SA was insensitive to the protein synthesis inhibitor cycloheximide, but was subst

157 gulate CXCR4 expression was abrogated by the protein synthesis inhibitor cycloheximide, clearly indic

158 oproteins by responders was resistant to the protein synthesis inhibitor cycloheximide, coincided wit

159 FQR1 mRNA abundance is not diminished by the protein synthesis inhibitor cycloheximide, demonstrating

160 ol receptor cell line in the presence of the protein synthesis inhibitor cycloheximide, indicating th

161 In the presence of the protein synthesis inhibitor cycloheximide, LPS primarily

162 Sensitivity of the MDR RV+ cells to the protein synthesis inhibitor cycloheximide, saponin, and

163 In the presence of de novo protein synthesis inhibitor cycloheximide, SGN-40 signif

164 DR) action, and can occur in the presence of protein synthesis inhibitor cycloheximide, showing that

165 nscription is induced in the presence of the protein synthesis inhibitor cycloheximide, so it appears

166 d apoptosis did occur in the presence of the protein synthesis inhibitor cycloheximide, suggesting th

167 affected keratinocytes were treated with the protein synthesis inhibitor cycloheximide, the steady-st

168 Using the protein synthesis inhibitor cycloheximide, we investigat

169 ver of FOXM1 in MCF-7 cells treated with the protein synthesis inhibitor cycloheximide, whereas overe

170 Finally, the protein synthesis inhibitor cycloheximide, which complet

171 ent fibroblasts, even in the presence of the protein synthesis inhibitor cycloheximide, while Ski is

172 y H2O2 and the induction is sensitive to the protein synthesis inhibitor cycloheximide.

173 tein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide.

174 is ineffective unless in the presence of the protein synthesis inhibitor cycloheximide.

175 n by "superinduction" in the presence of the protein synthesis inhibitor cycloheximide.

176 a reappearance was completely blocked by the protein synthesis inhibitor cycloheximide.

177 c bcl-2 family member bax or addition of the protein synthesis inhibitor cycloheximide.

178 aspartate receptor antagonist MK-801 and the protein synthesis inhibitor cycloheximide.

179 coid dexamethasone and were augmented by the protein synthesis inhibitor cycloheximide.

180 n band, effects that were insensitive to the protein synthesis inhibitor cycloheximide.

181 -alpha in the same cells pretreated with the protein synthesis inhibitor cycloheximide.

182 ent with the antiestrogen ICI 182,780 or the protein synthesis inhibitor cycloheximide.

183 serial FACS analyses in the presence of the protein synthesis inhibitor cycloheximide.

184 nt in the absence but not in the presence of protein synthesis inhibitor cycloheximide.

185 TNF-alpha expression in the presence of the protein synthesis inhibitor cycloheximide.

186 Using the protein synthesis inhibitors cycloheximide and anisomyci

187 Here, we show that the application of protein synthesis inhibitors cycloheximide and emetine t

188 ment for at least 12 h and is blocked by the protein synthesis inhibitors cycloheximide and puromycin

189 The protein synthesis inhibitors cycloheximide and puromycin

190 The protein synthesis inhibitors cycloheximide and puromycin

191 incorporation was blocked completely by the protein synthesis inhibitors cycloheximide and puromycin

192 On the contrary, treatment with the protein synthesis inhibitors cycloheximide, anisomycin,

193 ynthesis as shown by cell treatment with the protein-synthesis inhibitor cycloheximide.

194 induced by TNF- alpha in the presence of the protein-synthesis inhibitor cycloheximide.

195 Exploration of the effects of other protein synthesis inhibitors (cycloheximide, anisomycin)

196 Pretreatment with the protein synthesis inhibitor, cycloheximide (CHX, 100 mic

197 Prior treatment of rats with the protein synthesis inhibitor, cycloheximide, also blunted

198 Interestingly, the protein synthesis inhibitor, cycloheximide, and protein

199 ective effect was abolished by injecting the protein synthesis inhibitor, cycloheximide, and the affe

200 The protein synthesis inhibitor, cycloheximide, blocked the

201 hronic administration of anti-rat p75 or the protein synthesis inhibitor, cycloheximide, but not anti

202 obility shift of p66shc was inhibited by the protein synthesis inhibitor, cycloheximide, but not by t

203 The eukaryotic protein synthesis inhibitor, cycloheximide, caused a >50

204 nd the Notch pathway, or by treatment with a protein synthesis inhibitor, cycloheximide, leads to the

205 ed to apoptosis either by cotreatment with a protein synthesis inhibitor, cycloheximide, or Smac mime

206 s new protein synthesis, as treatment with a protein synthesis inhibitor, cycloheximide, partially re

207 In the presence of a protein synthesis inhibitor, cycloheximide, tumor necros

208 synthesis inhibitor, actinomycin-D, and the protein synthesis inhibitor, cycloheximide, were examine

209 in response to mechanical agitation and the protein synthesis inhibitor, cycloheximide.

210 ase in Ivr2 transcripts was sensitive to the protein synthesis inhibitor, cycloheximide.

211 rown in low concentrations of the eukaryotic protein synthesis inhibitor, cycloheximide.

212 eath in DIV 7-8 neurons was prevented by the protein-synthesis inhibitor, cycloheximide.

213 478, and re-expression was prohibited by the protein synthesis inhibitor cylcoheximide; the lysosome

214 Protein synthesis inhibitors did not prevent Theta Bust

215 e prolonged 1-Hz stimulus in the presence of protein synthesis inhibitors each can be transformed int

216 Additionally, pretreatment with the protein synthesis inhibitor emetine (1 microM) totally p

217 Bath application of the protein synthesis inhibitor emetine or cycloheximide 1 h

218 amtide-2-related inhibitory peptide, and the protein synthesis inhibitors emetine and anisomycin.

219 influx (diazoxide or nimodipine), whereas a protein synthesis inhibitor (emetine) decreased it by on

220 otonin receptor antagonist (methysergide) or protein synthesis inhibitors (emetine or cycloheximide)

221 on develops slowly and may be treatable with protein synthesis inhibitors, even when treatment is del

222 imals that were injected previously with the protein synthesis inhibitor exhibited significantly less

223 al prevented the memory-impairing effects of protein synthesis inhibitors following retrieval.

224 lipid moieties in the presence or absence of protein synthesis inhibitors had no effect on epithelial

225 tent with this idea was the finding that the protein synthesis inhibitors had no measurable effect on

226 ffects that cell-wall active antibiotics and protein-synthesis inhibitors have on transcription and t

227 RA's effect was blocked by either RNA or protein synthesis inhibitors; however, hCAR mRNA's stabi

228 ctrotransformation before selection with the protein synthesis inhibitor hygromycin B was imposed.

229 ection is sensitive to transcription but not protein synthesis inhibitors, implicating a pretranslati

230 ere we show that anisomycin, a commonly used protein synthesis inhibitor in memory research, impairs

231 Thus, the effect of protein synthesis inhibitors in stabilizing the GPI-PLC

232 cells, and the effect of transcriptional and protein synthesis inhibitors indicates de novo IL-10 pro

233 till initiates when embryos are treated with protein synthesis inhibitors, indicating that it is medi

234 STM for FC can occur even in the presence of protein synthesis inhibitors, indicating that redistribu

235 properties are lacking in engram cells under protein synthesis inhibitor-induced amnesia, direct opto

236 In addition, cycloheximide (10 microM), a protein synthesis inhibitor, inhibited the effect of str

237 This OM effect was not blocked by protein synthesis inhibitors, inhibitors of p38 kinase,

238 yos or embryos arrested in interphase with a protein synthesis inhibitor, injection of CycB accelerat

239 Finally, injection of a protein synthesis inhibitor into either ilPFC or CeA imp

240 s preceded by bilateral microinjections of a protein synthesis inhibitor into the basolateral amygdal

241 Postsession infusion of a protein synthesis inhibitor into the prelimbic cortex di

242 Although injecting the protein-synthesis inhibitor into the dorsal hippocampus

243 trast, bilateral injections of anisomycin, a protein synthesis inhibitor, into BLA did not impair the

244 f rats received 0.4 mg/kg cycloheximide, the protein synthesis inhibitor, intraperitoneally before pr

245 ar osmotic shock and certain phosphatase and protein synthesis inhibitors, leads to phosphorylation o

246 method, we use drug combinations comprising protein synthesis inhibitors (macrolides, aminoglycoside

247 However, protein synthesis inhibitors may have additional detrime

248 ed by nifedipine was not prevented by RNA or protein synthesis inhibitors, nor by the caspase inhibit

249 tro, but little is known about the effect of protein synthesis inhibitors on either induction or main

250 Furthermore, incubation with a protein synthesis inhibitor or an NMDAR-antagonist impai

251 ked by tyrosine kinase inhibition but not by protein synthesis inhibitors or cytochalasin D.

252 Treatment with protein synthesis inhibitors or the expression of the do

253 The DNA degradation was insensitive to protein synthesis inhibitors or UV inactivation of virus

254 Anisomycin (protein synthesis inhibitor) or KT5720 (protein kinase A

255 ately by intra-LA infusions of anisomycin (a protein synthesis inhibitor) or Rp-cAMPS (an inhibitor o

256 session, either a solution of anisomycin (a protein synthesis inhibitor) or vehicle was bilaterally

257 ed Sar1p mutant protein in the presence of a protein synthesis inhibitor, or by plasmid-encoded expre

258 cells, the addition of either anisomycin, a protein synthesis inhibitor, or geranylgeraniol, an inte

259 With protein synthesis inhibitors, phrenic LTF differed from

260 tibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor antimycobacterial acti

261 -such that when presented in the presence of protein synthesis inhibitors produce a rapid reversal of

262 cium chelation and by preincubation with the protein synthesis inhibitor puromycin.

263 Incubation with the protein synthesis inhibitor rapamycin during the second

264 tivation was followed by incubation with the protein synthesis inhibitor rapamycin.

265 Infusion of protein synthesis inhibitors (rapamycin or anisomycin) i

266 ent of resistant cells with cycloheximide (a protein synthesis inhibitor) rendered cells sensitive to

267 ing culture of VZ cells in the presence of a protein synthesis inhibitor results after 20 h in a loss

268 cell line by treatment with cycloheximide, a protein synthesis inhibitor, showing that the level of A

269 Here we show that YoeB, a highly potent protein synthesis inhibitor, specifically blocks transla

270 further experiments demonstrated that these protein synthesis inhibitors stimulated rapid and differ

271 Finally, the protein synthesis inhibitors Stx1 and anisomycin trigger

272 Amnesia produced by protein synthesis inhibitors such as anisomycin provides

273 This view stems from the observation that protein synthesis inhibitors, such as anisomycin (ANI),

274 but does not affect sensitivity toward other protein synthesis inhibitors, such as saporin or cyclohe

275 The use of protein synthesis inhibitors suggested that newly synthe

276 al inhibitor) as well as by cycloheximide (a protein synthesis inhibitor), suggesting the involvement

277 anscriptional levels and was unaffected by a protein synthesis inhibitor, suggesting that this did no

278 e transcriptional level and was sensitive to protein synthesis inhibitors, suggesting a requirement f

279 ion in Fragile X mutants could be rescued by protein synthesis inhibitors, suggesting that excess bas

280 en gene expression, whereas cycloheximide, a protein synthesis inhibitor, superinduced the expression

281 Harringtonine, a structurally unrelated protein synthesis inhibitor that competes with trichothe

282 Omacetaxine mepesuccinate is a protein synthesis inhibitor that has demonstrated activi

283 deoxyadenosine (cladribine) and puromycin, a protein synthesis inhibitor that is often used as a domi

284 Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneup

285 Streptogramins A is a class of protein synthesis inhibitors that target the peptidyl tr

286 erience and shortly afterward treated with a protein synthesis inhibitor, the consolidated memory for

287 We found that the addition of protein synthesis inhibitors to acute slices (in which s

288 be restored by the selective application of protein synthesis inhibitors to distal axons.

289 strategy in KSHV-infected cells treated with protein synthesis inhibitors to identify direct transcri

290 Addition of protein synthesis inhibitors to TRAIL-resistant melanoma

291 Furthermore, our data show that the protein synthesis inhibitors used previously to test the

292 e inclusion by incubation in the presence of protein synthesis inhibitors, vesicles containing elemen

293 f conditioned responses, indicating that the protein synthesis inhibitor was applied to the eyeblink-

294 It was prevented when cycloheximide, a protein synthesis inhibitor, was added up to 6 hr after

295 Using protein synthesis inhibitors we showed that the degradat

296 When protein synthesis inhibitors were added 15 min before ad

297 indicated that the new macrolides are potent protein synthesis inhibitors, which interact with methyl

298 yed increase in synaptotagmin was blocked by protein synthesis inhibitors, while the early increase i

299 hypotheses that delayed administration of a protein synthesis inhibitor would be effective in reduci

300 ypothesized that the use of a bacteriostatic protein synthesis inhibitor would improve outcomes by re